Drug Approval | March 29, 2023
Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Granules now have a total of 53 ANDA approvals from USFDA
Subscribe To Our Newsletter & Stay Updated
